EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Invex Therapeutics's enterprise value is A$0.16 Mil.
Invex Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-6.83 Mil. Therefore, Invex Therapeutics's EV-to-EBITDA for today is -0.02.
The historical rank and industry rank for Invex Therapeutics's EV-to-EBITDA or its related term are showing as below:
ASX:IXC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -76.12 Med: 0 Max: 2.89
Current: -0.02
During the past 4 years, the highest EV-to-EBITDA of Invex Therapeutics was 2.89. The lowest was -76.12. And the median was 0.00.
ASX:IXC's EV-to-EBITDA is ranked worse than 100% of 451
companies
in the Biotechnology industry
Industry Median: 9.67
vs ASX:IXC: -0.02
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Invex Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Invex Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Invex Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Invex Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invex Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Invex Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Invex Therapeutics's EV-to-EBITDA falls into.
Invex Therapeutics's current Enterprise Value is A$0.16 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Invex Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-6.83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Invex Therapeutics's PE Ratio for today is calculated as:
Invex Therapeutics's share price for today is A$0.084.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Invex Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.080.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Invex Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:IXC has been successfully added to your 